{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:35:58Z","timestamp":1790087758356,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T00:00:00Z","timestamp":1485475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T00:00:00Z","timestamp":1485475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Risk assessment in patients with acute coronary syndromes (ACS) is critical in order to provide adequate treatment. We performed a systematic meta-analysis to assess the predictive role of serum C-reactive protein (CRP) in patients with ST-segment elevation myocardial infarction (STEMI), treated with primary percutaneous coronary intervention (PPCI). We included 7 studies, out of 1,033 studies, with a total of 6,993 patients with STEMI undergoing PPCI, which were divided in the high or low CRP group, according to the validated cut-off values provided by the corresponding CRP assay. High CRP values were associated with increased in-hospital and follow-up all-cause mortality, in-hospital and follow-up major adverse cardiac events (MACE), and recurrent myocardial infarction (MI). The pre-procedural CRP predicted in-hospital target vessel revascularization (TVR), but was not associated with acute\/subacute and follow-up in-stent restenosis (ISR), and follow-up TVR. Thus, pre-procedural serum CRP could be a valuable predictor of global cardiovascular risk, rather than a predictor of stent-related complications in patients with STEMI undergoing PPCI. This biomarker might have the potential to improve the management of these high-risk patients.<\/jats:p>","DOI":"10.1038\/srep41530","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T11:59:53Z","timestamp":1485518393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis"],"prefix":"10.1038","volume":"7","author":[{"given":"Raluca-Ileana","family":"Mincu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf Alexander","family":"J\u00e1nosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,27]]},"reference":[{"key":"BFsrep41530_CR1","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs289","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg, P. G. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33, 2569\u20132619 (2012).","journal-title":"Eur. Heart J."},{"key":"BFsrep41530_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"CK Hansson","year":"2005","unstructured":"Hansson, C. K. Inflammation, atherosclerosis and coronary artery disease. N. Engl. J. Med. 352, 1685\u20131695 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep41530_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1136\/heart.83.3.361","volume":"83","author":"MJ Davies","year":"2000","unstructured":"Davies, M. J. The pathophysiology of acute coronary syndromes. Heart. 83, 361\u2013366 (2000).","journal-title":"Heart"},{"key":"BFsrep41530_CR4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/bmj.326.7401.1259","volume":"326","author":"ED Grech","year":"2003","unstructured":"Grech, E. D. & Ramsdale, D. R. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. BMJ. 326, 1259\u20131261 (2003).","journal-title":"BMJ"},{"key":"BFsrep41530_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/01.NAJ.0000351508.39509.e2","volume":"109","author":"KJ Overbaugh","year":"2009","unstructured":"Overbaugh, K. J. Acute coronary syndrome. Am. J. Nurs. 109, 42\u201352 (2009).","journal-title":"Am. J. Nurs."},{"key":"BFsrep41530_CR6","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/eurheartj\/ehq326","volume":"31","author":"KA Fox","year":"2010","unstructured":"Fox, K. A. et al. Underestimated and underrecognized: the late consequences of acute coronary syndrome (GRACE UK\u2013 Belgian Study). Eur. Heart J. 31, 2755\u20132764 (2010).","journal-title":"Eur. Heart J."},{"key":"BFsrep41530_CR7","doi-asserted-by":"publisher","first-page":"E96","DOI":"10.1016\/S0735-1097(13)60097-2","volume":"61","author":"A Marceau","year":"2013","unstructured":"Marceau, A., Samson, J. M., Laflamme, N. & Rinfret, S. Short and long-term mortality after STEMI versus NON-STEMI: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 61, E96 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep41530_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/01.CIR.0000029802.88087.5E","volume":"106","author":"S Verma","year":"2002","unstructured":"Verma, S. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106, 913\u2013919 (2002).","journal-title":"Circulation"},{"key":"BFsrep41530_CR9","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/01.CIR.0000015126.83143.B4","volume":"105","author":"S Verma","year":"2002","unstructured":"Verma, S. et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105, 1890\u20131896 (2002).","journal-title":"Circulation"},{"key":"BFsrep41530_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2005.09.023","volume":"187","author":"SM Boekholdt","year":"2006","unstructured":"Boekholdt, S. M. et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993\u20132003. Atherosclerosis 187, 415\u2013422 (2006).","journal-title":"Atherosclerosis"},{"key":"BFsrep41530_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/eurheartj\/ehi237","volume":"26","author":"DE Laaksonen","year":"2005","unstructured":"Laaksonen, D. E. et al. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur. Heart J. 26, 1783\u20131789 (2005).","journal-title":"Eur. Heart J."},{"key":"BFsrep41530_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1161\/01.CIR.99.2.237","volume":"99","author":"W Koenig","year":"1999","unstructured":"Koenig, W. et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99, 237\u2013242 (1999).","journal-title":"Circulation"},{"key":"BFsrep41530_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/ncpcardio1322","volume":"5","author":"K Musunuru","year":"2008","unstructured":"Musunuru, K. et al. The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat. Clin. Pract. Cardiovasc. Med. 5, 621\u2013635 (2008).","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"BFsrep41530_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","volume":"367","author":"S Kaptoge","year":"2012","unstructured":"Kaptoge, S. et al. C-reactive protein, fibrinogen and cardiovascular disease prediction. N. Engl. J. Med. 367, 1310\u20131320 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep41530_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.carrev.2014.02.003","volume":"15","author":"G Ndrepepa","year":"2014","unstructured":"Ndrepepa, G. et al. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. Cardiovasc. Revasc. Med. 15, 131\u2013136 (2014).","journal-title":"Cardiovasc. Revasc. Med"},{"key":"BFsrep41530_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.5551\/jat.18705","volume":"20","author":"T Nozue","year":"2013","unstructured":"Nozue, T. et al. C-reactive protein and future cardiovascular events in statin-treated patients with angina pectoris: the extended TRUTH study. J. Atheroscler. Thromb. 20, 717\u2013725 (2013).","journal-title":"J. Atheroscler. Thromb"},{"key":"BFsrep41530_CR17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.amjcard.2005.12.037","volume":"15","author":"CM Gibson","year":"2006","unstructured":"Gibson, C. M. et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am. J. Cardiol. 15, 1473\u20131477 (2006).","journal-title":"Am. J. Cardiol."},{"key":"BFsrep41530_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1253\/circj.CJ-08-0185","volume":"72","author":"T Nakachi","year":"2008","unstructured":"Nakachi, T. et al. C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ. J. 72, 1953\u20131959 (2008).","journal-title":"Circ. J."},{"key":"BFsrep41530_CR19","first-page":"e25414","volume":"4","author":"S Abdi","year":"2015","unstructured":"Abdi, S. et al. Evaluation of the Clinical and Procedural Predictive Factors of no-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention. Res. Cardiovasc. Med. 4, e25414 (2015).","journal-title":"Res. Cardiovasc. Med"},{"key":"BFsrep41530_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.carrev.2009.01.005","volume":"10","author":"C Delhaye","year":"2009","unstructured":"Delhaye, C. et al. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention. Cardiovasc. Revasc. Med. 10, 144\u2013150 (2009).","journal-title":"Cardiovasc. Revasc. Med"},{"key":"BFsrep41530_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ahj.2009.05.026","volume":"158","author":"L Razzouk","year":"2009","unstructured":"Razzouk, L. et al. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am. Heart J. 158, 277\u2013283 (2009).","journal-title":"Am. Heart J."},{"key":"BFsrep41530_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/hrt.2008.153635","volume":"95","author":"R Iijima","year":"2009","unstructured":"Iijima, R. et al. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart 95, 107\u2013112 (2009).","journal-title":"Heart"},{"key":"BFsrep41530_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10753-014-0018-8","volume":"38","author":"SB Bibek","year":"2015","unstructured":"Bibek, S. B. et al. Role of pre-procedural C-reactive protein level in the prediction of major adverse cardiac events in patients undergoing percutaneous coronary intervention: a meta-analysis of longitudinal studies. Inflammation 38, 159\u2013169 (2015).","journal-title":"Inflammation"},{"key":"BFsrep41530_CR24","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"S Windecker","year":"2014","unstructured":"Windecker, S. et al. 2014 ESC\/EACTS Guidelines on myocardial revascularization. Eu. Heart J. 35, 2541\u20132619 (2014).","journal-title":"Eu. Heart J"},{"key":"BFsrep41530_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","volume":"361","author":"EC Keeley","year":"2003","unstructured":"Keeley, E. C., Boura, J. A. & Grines, C. L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361,13\u201320 (2003).","journal-title":"Lancet"},{"key":"BFsrep41530_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/eurheartj\/ehm338","volume":"29","author":"P Ortolani","year":"2008","unstructured":"Ortolani, P. et al. Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur. Heart J. 29, 1241\u20131249 (2008).","journal-title":"Eur. Heart J."},{"key":"BFsrep41530_CR27","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.amjcard.2011.01.042","volume":"107","author":"MM Schoos","year":"2011","unstructured":"Schoos, M. M. et al. Usefulness of preprocedure high-sensitivity C-reactive protein to predict death, recurrent myocardial infarction, and stent thrombosis according to stent type in patients with ST-segment elevation myocardial infarction randomized to bare metal or drug-eluting stenting during primary percutaneous coronary intervention. Am. Cardiol. 107, 1597\u20131603 (2011).","journal-title":"Am. Cardiol."},{"key":"BFsrep41530_CR28","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mhj.2000.108244","volume":"140","author":"H Tomoda","year":"2000","unstructured":"Tomoda, H. & Aoki, N. Prognostic value of C-reactive protein levels within six hours after the onset of acute myocardial infarction. Am. Heart J. 140, 324\u2013328 (2000).","journal-title":"Am. Heart J."},{"key":"BFsrep41530_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacc.2010.06.053","volume":"57","author":"P Damman","year":"2011","unstructured":"Damman, P. et al. Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 57, 29\u201336 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep41530_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/clc.20403","volume":"31","author":"YH Jeong","year":"2008","unstructured":"Jeong, Y. H. et al. Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. Clin. Cardiol. 31, 572\u2013579 (2008).","journal-title":"Clin. Cardiol."},{"key":"BFsrep41530_CR31","doi-asserted-by":"publisher","first-page":"664","DOI":"10.4070\/kcj.2013.43.10.664","volume":"43","author":"KH Kim","year":"2013","unstructured":"Kim, K. H. et al. The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention. Korean Circ J. 43, 664\u2013673 (2013).","journal-title":"Korean Circ J"},{"key":"BFsrep41530_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/clc.4960270314","volume":"27","author":"R Magadle","year":"2004","unstructured":"Magadle, R. et al. The relation between preprocedural C-reactive protein levels and early and late complications in patients with acute myocardial infarction undergoing interventional coronary angioplasty. Clin. Cardiol. 27, 163\u2013168 (2004).","journal-title":"Clin. Cardiol."},{"key":"BFsrep41530_CR33","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi, M. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 37, 267\u2013315 (2016).","journal-title":"Eur. Heart J."},{"key":"BFsrep41530_CR34","unstructured":"Catapano, A. L. et al. 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. - Advance Access published August 27 (2016)."},{"key":"BFsrep41530_CR35","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff","year":"2014","unstructured":"Goff, D. C. et al. 2013 ACC\/AHA Guideline on the Assessment of Cardiovascular Risk Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129, S49\u2013S73 (2014).","journal-title":"Circulation"},{"key":"BFsrep41530_CR36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/hrt.2006.099762","volume":"93","author":"DW Park","year":"2007","unstructured":"Park, D. W. et al. Prognostic impact of preprocedural C-reactive protein levels on six-month angiographic and one-year clinical outcomes after drug-eluting stnet implantation. Heart 93, 1087\u20131092 (2007).","journal-title":"Heart"},{"key":"BFsrep41530_CR37","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.carrev.2008.01.003","volume":"9","author":"G Ferrante","year":"2008","unstructured":"Ferrante, G. et al. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc. Revasc. Med. 9, 156\u2013165 (2008).","journal-title":"Cardiovasc. Revasc. Med."},{"key":"BFsrep41530_CR38","doi-asserted-by":"publisher","first-page":"e0138512","DOI":"10.1371\/journal.pone.0138512","volume":"10","author":"IC Hsieh","year":"2015","unstructured":"Hsieh, I. C. et al. Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months after Drug-Eluting Stent Implantation. PLoS One. 10, e0138512 (2015).","journal-title":"PLoS One."},{"key":"BFsrep41530_CR39","first-page":"49","volume":"37","author":"JJ Li","year":"2010","unstructured":"Li, J. J. et al. Impact of C reactive protein on in-stent restenosis: a meta-analysis. Tex Heart Inst. J. 37, 49\u201357 (2010).","journal-title":"Tex Heart Inst. J"},{"key":"BFsrep41530_CR40","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1093\/eurheartj\/eht435","volume":"34","author":"LM Biasucci","year":"2013","unstructured":"Biasucci, L. M. et al. How to use C-reactive protein in acute coronary care. Eu. Heart J. 34, 3687\u20133690 (2013).","journal-title":"Eu. Heart J"},{"key":"BFsrep41530_CR41","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195\u20132207 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep41530_CR42","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/eurheartj\/ehr262","volume":"33","author":"PS Server","year":"2012","unstructured":"Server, P. S. et al. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur. Heart J. 33, 486\u2013494 (2012).","journal-title":"Eur. Heart J."},{"key":"BFsrep41530_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker, P. M. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20\u201328 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep41530_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa042000","volume":"352","author":"SE Nissen","year":"2005","unstructured":"Nissen, S. E. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29\u201338 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep41530_CR45","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","volume":"32","author":"P Libby","year":"2012","unstructured":"Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 2045\u201351 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFsrep41530_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/01.ATV.0000251503.35795.4f","volume":"27","author":"W Koenig","year":"2007","unstructured":"Koenig, W. & Khuseyinova, N. Biomarkers of atherosclerotic plaque instability and rupture. Aterioscler. Thromb. Vasc. Biol. 27, 15\u201327 (2007).","journal-title":"Aterioscler. Thromb. Vasc. Biol"},{"key":"BFsrep41530_CR47","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 151, W65\u201394 (2009).","journal-title":"Ann. Intern. Med."},{"key":"BFsrep41530_CR48","unstructured":"Wells, G. A. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (2011)."},{"key":"BFsrep41530_CR49","unstructured":"Higgings, J. & Green, D. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration. www.cochrane-handbook.org (2011)."},{"key":"BFsrep41530_CR50","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology, a proposal for reporting. JAMA 283, 2008\u20132012 (2000).","journal-title":"JAMA"},{"key":"BFsrep41530_CR51","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/SMJ.0b013e31817a7ee4","volume":"101","author":"AJ Viera","year":"2008","unstructured":"Viera, A. J. Odds ratios and risk ratios: what\u2019s the difference and why does it matter? South Med. J. 101, 730\u2013734 (2008).","journal-title":"South Med. J."},{"key":"BFsrep41530_CR52","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539\u20131558 (2002).","journal-title":"Stat. Med."},{"key":"BFsrep41530_CR53","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 315, 629\u2013634 (1997).","journal-title":"BMJ"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep41530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep41530","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep41530.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T21:05:43Z","timestamp":1671829543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep41530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,27]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,13]]}},"alternative-id":["BFsrep41530"],"URL":"https:\/\/doi.org\/10.1038\/srep41530","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,27]]},"assertion":[{"value":"12 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41530"}}